Imidacloprid Form I Crystallization with Low Dimer Impurity

The patent applies preliminary action by performing refinement of imidacloprid before the selective crystallization step. This preliminary refinement process removes dimer impurities and other contaminants from the imidacloprid sample, ensuring that the subsequent crystallization occurs from a purified substrate. By addressing the impurity problem before the critical crystallization step, the process enables selective formation of Form I without interference from dimer compounds that would otherwise inhibit polymorph selection.

The patent employs parameter changes by carefully controlling crystallization conditions including temperature, solvent type, and cooling rate to achieve selective formation of Form I. The refinement process also involves parameter optimization to effectively remove dimer impurities while preserving the imidacloprid structure. These controlled parameter changes enable transition from a system producing impure mixtures to one yielding pure Form I.

The refinement step serves as a preliminary action that prepares the imidacloprid material by removing impurities before the critical crystallization process. This ensures that when crystallization occurs, the reliable formation of Form I is not compromised by the presence of dimer or other impurities that would otherwise interfere with polymorph selection.

The patent creates an inert environment for crystallization by using carefully selected solvents and controlling the crystallization conditions to exclude interfering substances. The refinement process effectively creates a clean, inert substrate environment that allows the crystallization process to proceed reliably toward Form I without contamination from dimer impurities.